Cover

Chronic Pain and Addiction

Editor(s): Clark M.R. (Baltimore, Md.) 
Treisman G.J. (Baltimore, Md.) 
Table of Contents
Vol. 30, 2011
Section title: Paper
Clark MR, Treisman GJ (eds): Chronic Pain and Addiction. Adv Psychosom Med. Basel, Karger, 2011, vol 30, pp 22–60
(DOI:10.1159/000324065)

Addiction and Brain Reward and Antireward Pathways

Gardner E.L.
Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Addictive drugs have in common that they are voluntarily self-administered by laboratory animals (usually avidly), and that they enhance the functioning of the reward circuitry of the brain (producing the ‘high’ that the drug user seeks). The core reward circuitry consists of an ‘in-series’ circuit linking the ventral tegmental area, nucleus accumbens and ventral pallidum via the medial forebrain bundle. Although originally believed to simply encode the set point of hedonic tone, these circuits are now believed to be functionally far more complex, also encoding attention, expectancy of reward, disconfirmation of reward expectancy, and incentive motivation. ‘Hedonic dysregulation’ within these circuits may lead to addiction. The ‘second-stage’ dopaminergic component in this reward circuitry is the crucial addictive-drug-sensitive component. All addictive drugs have in common that they enhance (directly or indirectly or even transsynaptically) dop-aminergic reward synaptic function in the nucleus accumbens. Drug self-administration is regulated by nucleus accumbens dopamine levels, and is done to keep nucleus accumbens dopamine within a specific elevated range (to maintain a desired hedonic level). For some classes of addictive drugs (e.g. opiates), tolerance to the euphoric effects develops with chronic use. Postuse dysphoria then comes to dominate reward circuit hedonic tone, and addicts no longer use drugs to get high, but simply to get back to normal (‘get straight’). The brain circuits mediating the pleasurable effects of addictive drugs are anatomically, neurophysiologically and neurochemically different from those mediating physical dependence, and from those mediating craving and relapse. There are important genetic variations in vulnerability to drug addiction, yet environmental factors such as stress and social defeat also alter brain-reward mechanisms in such a manner as to impart vulnerability to addiction. In short, the ‘bio-psycho-social’ model of etiology holds very well for addiction. Addiction appears to correlate with a hypodopaminergic dysfunctional state within the reward circuitry of the brain. Neuroimaging studies in humans add credence to this hypothesis. Credible evidence also implicates serotonergic, opioid, endocannabinoid, GABAergic and glutamatergic mechanisms in addiction. Critically, drug addiction progresses from occasional recreational use to impulsive use to habitual compulsive use. This correlates with a progression from reward-driven to habit-driven drug-seeking behavior. This behavioral progression correlates with a neuroanatomical progression from ventral striatal (nucleus accumbens) to dorsal striatal control over drug-seeking behavior. The three classical sets of craving and relapse triggers are (a) reexposure to addictive drugs, (b) stress, and (c) reexposure to environmental cues (people, places, things) previously associated with drug-taking behavior. Drug-triggered relapse involves the nucleus accumbens and the neurotransmitter dopamine. Stress-triggered relapse involves (a) the central nucleus of the amygdala, the bed nucleus of the stria terminalis, and the neurotransmitter corticotrophin-releasing factor, and (b) the lateral tegmental noradrenergic nuclei of the brain stem and the neurotransmitter norepinephrine. Cue-triggered relapse involves the basolateral nucleus of the amygdala, the hippocampus and the neurotransmitter glutamate. Knowledge of the neuroanatomy, neurophysiology, neurochemistry and neuropharmacology of addictive drug action in the brain is currently producing a variety of strategies for pharmacotherapeutic treatment of drug addiction, some of which appear promising.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gardner EL: Brain reward mechanisms. (eds) Lowinson JH Ruiz P Millman RB Langrod JG: Substance Abuse. A Comprehensive Textbook 4 Philadelphia, Lippincott, Williams & Wilkins, 2005; 48-97
  2. Gardner EL: What we have learned about addiction from animal models of drug self-administration. Am J Addict 2000; 9: 285-313
  3. O’Brien CP Gardner EL: Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2005; 108: 18-58
  4. Gardner EL David J: The neurobiology of chemical addiction. (eds) Elster J Skog OJ: Getting Hooked. Rationality and the Addictions. Cambridge, Cambridge University Press, 1999; 93-136
  5. Wise RA Gardner EL: Functional anatomy of substance-related disorders;. (eds) D’Haenen H den Boer JA Willner P: Biological Psychiatry. New York, Wiley, 2002; 509-522
  6. Olds J Milner P: Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 1954; 47: 419-427
  7. Olds J: Pleasure centers in the brain. Sci Am 1956; 95: 105-116
  8. Olds J: Hypothalamic substrates of reward. Physiol Rev 1962; 42: 554-604
  9. Olds ME Olds J: Approach-avoidance analysis of rat diencephalon. J Comp Neurol 1963; 120: 259-295
  10. Olds ME Olds J: Drives, rewards and the brain;. (eds) Newcomb TM: New Directions in Psychology. New York, Holt, Rinehart & Winston, 1965; 329-410
  11. Routtenberg A Gardner EL Huang YH: Self-stimulation pathways in the monkey, Macaca mulatta. Exp Neurol 1971; 33: 213-224
  12. Gallistel CR Shizgal P Yeomans JS: A portrait of the substrate for self-stimulation. Psychol Rev 1981; 88: 228-273
  13. Wise RA Bozarth MA: Brain reward circuitry: four circuit elements ‘wired’ in apparent series. Brain Res Bull 1984; 12: 203-208
  14. Stuber GD van Leeuwen WA Sparta DR Zhang F Deisseroth K Bonci A: Optogenetic control of brain reward circuitry. Paper presented at meetings of the Society for Neuroscience, Chicago, 2009 (abstract No. 686.8) 2009 Abstract Viewer/Itinerary Planner CD-ROM, Thirty-Ninth Annual Meeting of the Society for Neuroscience, Chicago 2009; Washington, Society for Neuroscience, 2009;
  15. Alheid GF Heimer L: New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. Neuroscience 1988; 27: 1-39
  16. Hubner CB Koob GF: The ventral pallidum plays a role in mediating cocaine and heroin self-administration in the rat. Brain Res 1990; 508: 20-29
  17. Koob GF: Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992; 13: 177-184
  18. Kalivas PW Churchill L Klitenick MA: The circuitry mediating the translation of motivational stimuli into adaptive motor responses;. (eds) Kalivas PW Barnes CD: Limbic Motor Circuits and Neuropsychiatry. Boca Raton, CRC, 1993; 237-287
  19. Napier TC: Transmitter actions and interactions on pallidal neuronal function;. (eds) Kalivas PW Barnes CD: Limbic Motor Circuits and Neuropsychiatry. Boca Raton, CRC, 1993; 124-153
  20. Gong WH Neill D Justice JB Jr: Conditioned place preference and locomotor activation produced by injection of psychostimulants into ventral pallidum. Brain Res 1996; 707: 64-74
  21. Hasenöhrl RU Frisch C Huston JP: Evidence for anatomical specificity for the reinforcing effects of SP in the nucleus basalis magnocellularis region. Neuroreport 1998; 9: 7-10
  22. McBride WJ Murphy JM Ikemoto S: Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res 1999; 101: 129-152
  23. White NM Milner PM: The psychobiology of reinforcers. Annu Rev Psychol 1992; 43: 443-471
  24. Robbins TW Everitt BJ: Drug addiction: bad habits add up. Nature 1999; 398: 567-570
  25. Garavan H Pankiewicz J Bloom A Cho J-K Sperry L Ross TJ Salmeron BJ Risinger R Kelley D Stein EA: Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 2000; 157: 1789-1798
  26. Higgins JW Mahl GF Delgado JMR Hamlin H: Behavioral changes during intracerebral electrical stimulation. AMA Arch Neurol Psychiatry 1956; 76: 399-419
  27. Delgado JMR Hamlin H: Spontaneous and evoked electrical seizures in animals and in humans. (eds) Ramey ER O’Doherty DS: Electrical Studies on the Unanesthetized Brain. New York, Harper (Hoeber Medical Division), 1960; 133-158
  28. Heath RG Mickle WH: Evaluation of seven years’ experience with depth electrode studies in human patients. Ramey ER O’Doherty DS: Electrical Studies on the Unanesthetized Brain. New York, Harper (Hoeber Medical Division), 1960; 214-247
  29. Sem-Jacobsen W Torkildsen A: Depth recording and electrical stimulation in the human brain. Ramey ER O’Doherty DS: Electrical Studies on the Unanesthetized Brain. New York, Harper (Hoeber Medical Division), 1960; 280-288
  30. Bishop MP Elder ST Heath RG: Intracranial self-stimulation in man. Science 1963; 140: 394-396
  31. Heath RG: Electrical self-stimulation of the brain in man. Am J Psychiatry 1963; 120: 571-577
  32. Stein L Ray OS: Brain stimulation reward ‘thresholds’ self-determined in rat. Psychopharmacologia 1960; 1: 251-256
  33. Gardner EL: An improved technique for determining brain reward thresholds in primates. Behav Res Methods Instrum 1971; 3: 273-274
  34. Miliaressis E Rompré P-P Laviolette P Philippe L Coulombe D: The curve-shift paradigm in self-stimulation. Physiol Behav 1986; 37: 85-91
  35. Coulombe D Miliaressis E: Fitting intracranial self-stimulation data with growth models. Behav Neurosci 1987; 101: 209-214
  36. Anthony JC Warner LA Kessler RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychol 1994; 2: 244-268
  37. Vorel SR Ashby CR Jr Paul M Liu X Hayes R Hagan JJ Middlemiss DN Stemp G Gardner EL: Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J Neurosci 2002; 22: 9595-9603
  38. Pak AC Ashby CR Jr Heidbreder CA Pilla M Gilbert J Xi Z-X Gardner EL: The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006; 9: 585-602
  39. Spiller K Xi Z-X Peng X-Q Newman AH Ashby CR Jr Heidbreder CA Gaál J Gardner EL: The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain-stimulation reward in rats. Psychopharmacology 2008; 196: 533-542
  40. Xi Z-X Spiller K Pak AC Gilbert J Dillon C Li X Peng X-Q Gardner EL: Cannabinoid CB1 receptor antagonists attenuate cocaine’s rewarding effects: experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2008; 33: 1735-1745
  41. Li X Li J Peng X-Q Spiller K Gardner EL Xi Z-X: Metabotropic glutamate receptor 7 modulates cocaine’s rewarding effects in rats: involvement of a ventral pallidal GABAergic mechanism. Neuropsychopharmacology 2009; 34: 1783-1796
  42. Gardner EL Lowinson JH: Drug craving and positive/negative hedonic brain substrates activated by addicting drugs. Semin Neurosci 1993; 5: 359-368
  43. Xi Z-X Spiller K Gardner EL: Cannabinoid CB1 and CB2 receptors modulate brain reward function in opposite directions in rats. Paper presented at meetings of the Society for Neuroscience, Chicago, 2009 (abstract No. 449.13) 2009 Abstract Viewer/Itinerary Planner CD-ROM, Thirty-Ninth Annual Meeting of the Society for Neuroscience, Chicago 2009; Washington, Society for Neuroscience, 2009;
  44. Tzschentke TM: Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56: 613-672
  45. Tzschentke TM: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007; 12: 227-462
  46. Gardner EL Wise RA: Animal models of addiction. (eds) Charney DS Nestler EJ: Neurobiology of Mental Illness 3 Oxford, Oxford University Press, 2009; 757-774
  47. Yokel RA Wise RA: Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 1975; 187: 547-549
  48. Gardner EL Chen J Paredes W: Overview of chemical sampling techniques. J Neurosci Methods 1993; 48: 173-197
  49. Wise RA: In vivo estimates of extracellular dopamine and dopamine metabolite levels during intravenous cocaine or heroin self-administration. Semin Neurosci 1993; 5: 337-342
  50. Wise RA Leone P Rivest R Leeb K: Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse 1995; 21: 140-148
  51. Wise RA Newton P Leeb K Burnette B Pocock D Justice JB Jr: Fluctuations in nucleus accumbens dopamine concentration during intravenous cocaine self-administration in rats. Psychopharmacology 1995; 120: 10-20
  52. Solomon RL Corbit JD: An opponent-process theory of motivation. 1. Temporal dynamics of affect. Psychol Rev 1974; 81: 119-145
  53. Solomon RL: The opponent-process theory of acquired motivation: the costs of pleasure and the benefits of pain. Am Psychologist 1980; 35: 691-712
  54. Solomon RL: Recent experiments testing an opponent-process theory of acquired motivation. Acta Neurobiol Exp (Wars) 1980; 40: 271-289
  55. Koob GF Stinus L le Moal M Bloom FE: Opponent process theory of motivation: neurobiological evidence from studies of opiate dependence. Neurosci Biobehav Rev 1989; 13: 135-140
  56. Koob GF Caine SB Parsons L Markou A Weiss F: Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 1997; 57: 513-521
  57. Koob GF le Moal M: Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3113-3123
  58. Nazzaro JM Seeger TF Gardner EL: Morphine differentially affects ventral tegmental and substantia nigra brain reward thresholds. Pharmacol Biochem Behav 1981; 14: 325-331
  59. Broderick PA Gardner EL van Praag HM: In vivo electrochemical evidence for a differential enkephalinergic modulation of dopamine in rat nigrostriatal and mesolimbic systems: correlated behavioral stereotypy results. Paper presented at meetings of the International Narcotic Research Conference, Garmisch-Partenkirchen. 1983;
  60. Broderick PA Gardner EL van Praag HM: In vivo electrochemical and behavioral evidence for specific neural substrates modulated differentially by enkephalin in rat stimulant stereotypy and locomotion. Biol Psychiatry 1984; 19: 45-54
  61. Kokkinidis L McCarter BD: Postcocaine depression and sensitization of brain-stimulation reward: analysis of reinforcement and performance effects. Pharmacol Biochem Behav 1990; 36: 463-471
  62. Markou A Koob GF: Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuro-psychopharmacology 1991; 4: 17-26
  63. Schulteis G Markou A Cole M Koob GF: Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 1995; 92: 5880-5884
  64. Gardner EL Lepore M: Withdrawal from a single small dose of marijuana elevates baseline brain-stimulation reward thresholds in rats. Paper presented at Winter Conference on Brain Research, Aspen 1996;
  65. Epping-Jordan MP Watkins SS Koob GF Markou A: Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998; 393: 76-79
  66. Blum K Cull JG Braverman ER Comings DE: Reward deficiency syndrome. Am Sci 1996; 84: 132-145
  67. Blum K Sheridan PJ Wood RC Braverman ER Chen TJH Cull JG Comings DE: The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996; 89: 396-400
  68. Gardner EL Blum K: Neurobiology and genetics of addiction: implications of ‘reward deficiency syndrome’ for therapeutic strategies in chemical dependency. Paper presented at Russell Sage Foundation Conference on Addiction New York, 1997;
  69. Gardner EL: Neurobiology and genetics of addiction: implications of ‘reward deficiency syndrome’ for therapeutic strategies in chemical dependency. (eds) Elster J: Addiction. Entries and Exits. New York, Russell Sage Foundation, 1999; 57-119
  70. Comings DE Blum K: Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000; 126: 325-341
  71. Gardner EL: Reward behaviors as a function of hypo-dopaminergic activity: animal models of reward deficiency syndrome. Mol Psychiatry 2001; 6: ((suppl 1)) S4
  72. Blum K Noble EP Sheridan PJ Montgomery A Ritchie T Jadadeeswaran P Nogami H Briggs AH Cohn JB: Allelic association of the human dopamine D2 receptor gene in alcoholism. JAMA 1990; 263: 2055-2059
  73. Volkow ND Wang G-J Fowler JS Logan J Gatley SJ Gifford A Hitzemann R Ding Y-S Pappas N: Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999; 156: 1440-1443
  74. Volkow ND Fowler JS Wang G-J Ding Y-S Gatley SJ: Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol 2002; 12: 557-566
  75. Volkow ND Wang G-J Fowler JS Thanos PP Logan J Gatley SJ Gifford A Ding Y-S Wong C Pappas N: Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002; 46: 79-82
  76. Volkow ND Wang G-J Telang F Fowler JS Logan J Jayne M Ma Y Pradhan K Wong C: Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci 2007; 27: 12700-12706
  77. Morgan D Grant KA Gage HD Mach RH Kaplan JR Prioleau O Nader SH Buchheimer N Ehrenkaufer RL Nader MA: Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat Neurosci 2002; 5: 169-174
  78. Dalley JW Fryer TD Brichard L Robinson ESJ Theobald DEH Lääne K Peña Y Murphy ER Shah Y Probst K Abakumova I Aigbirhio FI Richards HK Hong Y Baron J-C Everitt BJ Robbins TW: Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007; 315: 1267-1270
  79. Staley JK Mash DC: Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996; 16: 6100-6106
  80. Mash DC: Are neuroadaptations in D3 dopamine receptors linked to the development of cocaine dependence?. Mol Psychiatry 1997; 2: 7-8
  81. Gardner EL: Use of animal models to develop antiaddiction medications. Curr Psychiatry Rep 2008; 10: 377-384
  82. Xi Z-X Gardner EL: Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev 2008; 1: 303-327
  83. Xi Z-X Spiller K Gardner EL: Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin 2009; 30: 723-739
  84. Heidbreder CA Gardner EL Xi Z-X Thanos PK Mugnaini M Hagan JJ Ashby CR Jr: The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 2005; 49: 77-105
  85. Heidbreder CA Andreoli M Marcon C Hutcheson DM Gardner EL Ashby CR Jr: Evidence for the role of dopamine D3 receptors in oral operant alcohol self-administration and reinstatement of alcohol-seeking behavior in mice. Addict Biol 2007; 12: 35-50
  86. Beitner-Johnson D Guitart X Nestler EJ: Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins. Brain Res 1991; 561: 147-150
  87. Guitart X Beitner-Johnson D Marby DW Kosten TA Nestler EJ: Fischer and Lewis rat strains differ in basal levels of neurofilament proteins and their regulation by chronic morphine in the mesolimbic dopamine system. Synapse 1992; 12: 242-253
  88. Berrettini WH Ferraro TN Alexander RC Buchberg AM Vogel WH: Quantitative trait loci mapping of three loci controlling morphine preference using inbred mouse strains. Nat Genet 1994; 7: 54-58
  89. Crawley JN Belknap JK Collins A Crabbe JC Frankel W Henderson N Hitzemann RJ Maxson SC Miner LL Silva AJ Wehner JM Wynshaw-Boris A Paylor R: Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997; 132: 107-124
  90. Brodkin ES Carlezon WA Jr Haile CN Kosten TA Heninger GR Nestler EJ: Genetic analysis of behavioral, neuroendocrine, and biochemical parameters in inbred rodents: initial studies in Lewis and Fischer 344 rats and in A/J and C57BL/6J mice. Brain Res 1998; 805: 55-68
  91. McBride WJ Li TK: Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit RevNeurobiol 1998; 12: 339-369
  92. Crabbe JC Phillips TJ Buck KJ Cunningham CL Belknap JK: Identifying genes for alcohol and drug sensitivity: recent progress and future directions. Trends Neurosci 1999; 22: 173-179
  93. Nestler EJ: Genes and addiction. Nat Genet 2000; 26: 277-281
  94. Dole VP Nyswander M: A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193: 646-650
  95. Dole VP Nyswander ME Kreek MJ: Narcotic blockade: a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians 1966; 79: 122-136
  96. Wise RA: The dopamine synapse and the notion of ‘pleasure centers’ in the brain. Trends Neurosci 1980; 3: 91-95
  97. Lee R-S Criado JE Koob GF Henriksen SJ: Cellular responses of nucleus accumbens neurons to opiate-seeking behavior. 1. Sustained responding during heroin self-administration. Synapse 1999; 33: 49-58
  98. Schultz W Apicella P Scarnati E Ljungberg T: Neuronal activity in monkey ventral striatum related to the expectation of reward. J Neurosci 1992; 12: 4595-4610
  99. Chang J-Y Sawyer SF Lee R-S Woodward DJ: Electrophysiological and pharmacological evidence for the role of the nucleus accumbens in cocaine self-administration in freely moving rats. J Neurosci 1994; 14: 1224-1244
  100. Kobayashi S Schultz W: Influence of reward delays on responses of dopamine neurons. J Neurosci 2008; 28: 7837-7846
  101. Gregorios-Pippas L Tobler PN Schultz W: Short-term temporal discounting of reward value in human ventral striatum. J Neurophysiol 2009; 101: 1507-1523
  102. Hare TA O’Doherty J Camerer CF Schultz W Rangel A: Dissociating the role of the orbitalfrontal cortex and the striatum in the computation of goal values and prediction errors. J Neurosci 2008; 28: 5623-5630
  103. Peoples LL Uzwiak AJ Gee F Fabbricatore AT Muccino KJ Mohta BD West MO: Phasic accumbal firing may contribute to the regulation of drug taking during intravenous cocaine self-administration sessions. Ann NY Acad Sci 1999; 877: 781-787
  104. Peoples LL Cavanaugh D: Differential changes in signal and background firing of accumbal neurons during cocaine self-administration. J Neurophysiol 2003; 90: 993-1010
  105. Uhl GR: Molecular genetics of substance abuse vulnerability: remarkable recent convergence of genome scan results. Ann NY Acad Sci 2004; 1025: 1-13
  106. Uhl GR Drgan T Johnson C Fatusin OO Liu Q-R Contoreggi C Li C-Y Buck K Crabbe J: ‘Higher order’ addiction molecular genetics: convergent data from genome-wide association in humans and mice. Biochem Pharmacol 2008; 75: 98-111
  107. Khokhar JY Ferguson CS Zhu AZX Tyndale RF: Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. Annu Rev Pharmacol Toxicol 2010; 50: 39-61
  108. Piazza PV Maccari S Deminière JM le Moal M Mormède P Simon H: Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA 1991; 88: 2088-2092
  109. Deminière JM Piazza PV Guegan G Abrous N Maccari S le Moal M Simon H: Increased locomotor response to novelty and propensity to intravenous amphetamine self-administration in adult offspring of stressed mothers. Brain Res 1992; 586: 135-139
  110. Redolat R Pérez-Martinez A Carrasco MC Mesa P: Individual differences in novelty-seeking and behavioral responses to nicotine: a review of animal studies. Curr Drug Abuse Rev 2009; 2: 230-242
  111. Sher KJ Bartholow BD Wood MD: Personality and substance use disorders: a prospective study. J Consult Clin Psychol 2000; 68: 818-829
  112. Zuckerman M Kuhlman DM: Personality and risk-taking: common biosocial factors. J Pers 2000; 68: 999-1029
  113. Mitchell SH: Measuring impulsivity and modeling its association with cigarette smoking. Behav Cogn Neurosci Rev 2004; 3: 261-275
  114. Perkins KA Lerman C Coddington SB Jetton C Karelitz JL Scott JA Wilson AS: Initial nicotine sensitivity in humans as a function of impulsivity. Psychopharmacology 2008; 200: 529-544
  115. Crowley TJ Mikulich SK Macdonald M Young SE Zerbe GO: Substance-dependent, conduct-disordered adolescent males: severity of diagnosis predicts 2-year outcome. Drug Alcohol Depend 1998; 49: 225-237
  116. Regier DA Farmer ME Rae DS Locke BZ Keith D Judd LL Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990; 264: 2511-2518
  117. Kessler RC Crum RM Warner LA Nelson CB Schulenberg J Anthony JC: Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997; 53: 232-240
  118. Wilson JJ Levin FR: Attention deficit hyperactivity disorder (ADHD) and substance use disorders. Curr Psychiatry Rep 2001; 3: 497-506
  119. Wilens TE: Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 2004; 27: 283-301
  120. Koob GF le Moal M: Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24: 97-129
  121. Koob GF Ahmed SH Boutrel B Chen SA Kenny PJ Markou A O’Dell LE Parsons LH Sanna PP: Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 2004; 27: 739-749
  122. Koob GF: Hedonic homeostatic dysregulation as a driver of drug-seeking behavior. Drug Discov Today Dis Models 2008; 5: 207-215
  123. Lepore M Vorel R Gardner EL: Studies on the neuro-biological interrelationship between vulnerability to depression and vulnerability to drug abuse in animal models. Behav Pharmacol 1995; 6: ((suppl 1)) 82-84
  124. Phillips GD Howes SR Whitelaw RB Robbins TW Everitt BJ: Isolation rearing impairs the reinforcing efficacy of intravenous cocaine or intra-accumbens d-amphetamine: impaired response to intra-accumbens D1 and D2/D3 dopamine receptor antagonists. Psychopharmacology 1994; 115: 419-429
  125. Nader MA Morgan D Gage HD Nader SH Calhoun TL Buchheimer N Ehrenkaufer R Mach RH: PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci 2006; 9: 1050-1056
  126. Ginovart N Farde L Halldin C Swahn CG: Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 1999; 31: 154-162
  127. Ginovart N Wilson AA Houle S Kapur S: Amphetamine pretreatment induces a change in both D2-receptor density and apparent affinity: a [11C]raclopride positron emission tomography study in cats. Biol Psychiatry 2004; 55: 1188-1194
  128. Lee B London ED Poldrack RA Farahi J Nacca A Monterosso JR Mumford JA Bokarius AV Dahlbom M Mukherjee J Bilder RM Brody AL Mandelkern MA: Striatal dopamine D2/D3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009; 29: 14734-14740
  129. Belin D Mar AC Dalley JW Robbins TW Everitt BJ: High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008; 320: 1352-1355
  130. di Chiara G Bassareo V Fenu S de Luca MA Spina L Cadoni C Acquas E Carboni E Valentini V Lecca D: Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 2004; 47: ((suppl 1)) 227-241
  131. Wise RA: Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5: 483-494
  132. Ikemoto S Qin M Liu Z-H: The functional divide for primary reinforcement of D-amphetamine lies between the medial and lateral ventral striatum: is the division of the nucleus accumbens core, shell, and olfactory tubercle valid?. J Neurosci 2005; 25: 5061-5065
  133. Tiffany ST: A cognitive model of drug urges and drug-use behavior: role of automatic and non-automatic processes. Psychol Rev 1990; 97: 146-168
  134. O’Brien CP McLellan AT: Myths about the treatment of addiction. Lancet 1996; 347: 237-240
  135. Everitt BJ Dickinson A Robbins TW: The neuropsychological basis of addictive behaviour. Brain Res Rev 2001; 36: 129-138
  136. Everitt BJ Robbins TW: Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005; 8: 1481-1489
  137. Verdejo-García A Pérez-García M: Substance abusers’ self-awareness of the neurobehavioral consequences of addiction. Psychiatry Res 2008; 158: 172-180
  138. Goldstein R Craig AD Bechara A Garavan H Childress AR Paulus MP Volkow ND: The neuro-circuitry of impaired insight in drug addiction. Trends Cogn Sci 2009; 13: 372-380
  139. Childress AR Hole AV Ehrman RN Robbins SJ McLellan AT O’Brien CP: Cue reactivity and cue reactivity interventions in drug dependence. NIDA Res Monogr 1993; 137: 73-95
  140. Leshner AI: Addiction is a brain disease, and it matters. Science 1997; 278: 45-47
  141. O’Brien CP Childress AR Ehrman R Robbins SJ: Conditioning factors in drug abuse: can they explain compulsion?. J Psychopharmacol 1998; 12: 15-22
  142. Robbins TW Everitt BJ: Limbic-striatal memory systems and drug addiction. Neurobiol Learn Mem 2002; 78: 625-636
  143. White NM: Some highlights of research on the effects of caudate nucleus lesions over the past 200 years. Behav Brain Res 2009; 199: 3-23
  144. Haber SN Fudge JL McFarland NR: Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J Neurosci 2000; 20: 2369-2382
  145. Everitt BJ Belin D Economidou D Pelloux Y Dalley JW Robbins TW: Neural mechanisms underlying the vulnerability to develop compulsive drug-seeking habits and addiction. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3125-3135
  146. Letchworth SR Nader MA Smith HR Friedman DP Porrino LJ: Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys. J Neurosci 2001; 21: 2799-2807
  147. Porrino LJ Daunais JB Smith HR Nader MA: The expanding effects of cocaine: studies in a nonhuman primate model of cocaine self-administration. Neurosci Biobehav Rev 2004; 27: 813-820
  148. Volkow ND Wang G-J Telang F Fowler JS Logan J Childress AR Jayne M Ma YM Wong C: Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006; 26: 6583-6588
  149. Takahashi Y Roesch MR Stalnaker TA Schoenbaum G: Cocaine shifts the balance of associative encoding from ventral to dorsolateral striatum. Front Integr Neurosci 2007; 1: 11
  150. Bozarth MA Wise RA: Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 1984; 224: 516-517
  151. Pert A Yaksh T: Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Res 1974; 80: 135-140
  152. Melzack R Wall PD: Pain mechanisms: a new theory. Science 1965; 150: 971-979
  153. Schaible HG: Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol 2007; 177: 3-28
  154. D’Mello R Dickenson AH: Spinal cord mechanisms of pain. Br J Anaesth 2008; 101: 8-16
  155. Alcoholics Anonymous Alcoholics Anonymous Big Book 1. New York, Alcoholics Anonymous World Services, 1939;
  156. Shalev U Grimm JW Shaham Y: Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54: 1-42
  157. Shaham Y Shalev U Lu L de Wit H Stewart J: The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 2003; 168: 3-20
  158. Aguilar MA Rodriguez-Arias M Miñarro J: Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res Rev 2009; 59: 253-277
  159. Epstein DH Preston KL: The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology 2003; 168: 31-41
  160. Epstein DH Preston KL Stewart J Shaham Y: Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology 2006; 189: 1-16
  161. Stewart J: Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking. J Psychiatry Neurosci 2000; 25: 125-136
  162. Moore RY Bloom FE: Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci 1979; 2: 113-168
  163. Itoi K: Ablation of the central noradrenergic neurons for unraveling their roles in stress and anxiety. Ann NY Acad Sci 2008; 1129: 47-54
  164. Vorel SR Liu X Hayes RJ Spector JA Gardner EL: Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 2001; 292: 1175-1178
  165. Hayes RJ Vorel SR Spector J Liu X Gardner EL: Electrical and chemical stimulation of the basolateral complex of the amygdala reinstates cocaine-seeking behavior in the rat. Psychopharmacology 2003; 168: 75-83
  166. Koob GF: Stress, corticotropin-releasing factor, and drug addiction. Ann NY Acad Sci 1999; 897: 27-45
  167. Heilig M Koob GF: A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007; 30: 399-406
  168. Koob GF Zorrilla EP: Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor. Curr Opin Investig Drugs 2010; 11: 63-71
  169. Grimm JW Hope BT Wise RA Shaham Y: Neuroadaptation: incubation of cocaine craving after withdrawal. Nature 2001; 412: 141-142
  170. Grimm JW Lu L Hayashi T Hope BT Su T-P Shaham Y: Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J Neurosci 2003; 23: 742-747
  171. Lu L Hope BT Dempsey J Liu SY Bossert JM Shaham Y: Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 2005; 8: 212-219
  172. Lu L Uejima JL Gray SM Bossert JM Shaham Y: Systemic and central amygdala injections of the mGluR2/3 agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol Psychiatry 2007; 61: 591-598
  173. Xi Z-X Gilbert J Campos AC Kline N Ashby CR Jr Hagan JJ Heidbreder CA Gardner EL: Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology 2004; 176: 57-65
  174. Hebb DO: The Organization of Behavior. A Neuropsychological Theory. New York, Wiley, 1949;
  175. Chen BT Hopf W Bonci A: Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuse. Ann NY Acad Sci 2010; 1187: 129-139
  176. Thomas MJ Beurrier C Bonci A Malenka RC: Long-term depression in the nucleus accumbens: a neural correlate of behavioral sensitization to cocaine. Nat Neurosci 2001; 4: 1217-1223
  177. Hoffman AF Oz M Caulder T Lupica CR: Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid Exposure. J Neurosci 2003; 23: 4815-4820
  178. Fourgeaud L Mato S Bouchet D Hémar A Worley PF Manzoni OJ: A single in vivo exposure to cocaine abolishes endocannabinoid-mediated long-term depression in the nucleus accumbens. J Neurosci 2004; 24: 6939-6945
  179. Liu Q-S Pu L Poo M-M: Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 2005; 437: 1027-1031
  180. Tye KM Stuber GD de Ridder B Bonci A Janak PH: Rapid strengthening of thalamo-amygdala synapses mediates cue-reward learning. Nature 2008 453: 1253-1258
  181. Rademacher DJ Rosenkranz JA Morshedi MM Sullivan EM Meredith GE: Amphetamine-associated contextual learning is accompanied by structural and functional plasticity in the basolateral amygdala. J Neurosci 2010; 30: 4676-4686
  182. Pu L Bao G-B Xu N-J Ma L Pei G: Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. J Neurosci 2002; 22: 1914-1921
  183. Thompson AM Swant J Gosnell BA Wagner JJ: Modulation of long-term potentiation in the rat hippocampus following cocaine self-administration. Neuroscience 2004; 127: 177-185
  184. Kenney JW Gould TJ: Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine. Mol Neurobiol 2008; 38: 101-121
  185. Kasanetz F Deroche-Gamonet V Berson N Balado E Lafourcade M Manzoni O Piazza PV: Transition to addiction is associated with a persistent impairment in synaptic plasticity. Science 2010; 328: 1709-1712
  186. Gardner EL: Pain management and the so-called ‘risk’ of addiction. (eds) Smith H Passik SD: Pain and Chemical Dependency London, Oxford University Press, 2008; 427-435
  187. Narita M Kishimoto Y Ise Y Yajima Y Misawa K Suzuki T: Direct evidence for the involvement of the mesolimbic κ -opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 2005; 30: 111-118
  188. Ozaki S Narita M Narita M Ozaki M Khotib J Suzuki T: Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J Neurochem 2004; 88: 1389-1397
  189. Kinshore KR Desiraju T: Inhibition of positively rewarding behavior by the heightened aggressive state evoked either by pain-inducing stimulus or septal lesion. Indian J Physiol Pharmacol 1990; 34: 125-129
  190. Vaccarino AL Marek P Kest B Ben-Eliyahu S Couret LC Jr Kao B Liebeskind JC: Morphine fails to produce tolerance when administered in the presence of formalin pain in rats. Brain Res 1993; 627: 287-290
  191. UNAIDS (Joint United Nations Programme on HIV/AIDS) Cancer Pain Relief, with a Guide to Opioid Availability. 2. Geneva, World Health Organization, 1996; 24-37
  192. Stotts AL Dodrill CL Kosten TR: Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10: 1727-1740
  193. Lobmaier P Gossop M Waal H Bramness J: The pharmacological treatment of opioid addiction: a clinical perspective. Eur J Clin Pharmacol 2010; 66: 537-545
  194. Wakhlu S: Buprenorphine: a review. J Opioid Manag 2009; 5: 59-64
  195. Strang J Metrebian N Lintzeris N Potts L Carnwath T Mayet S Williams H Zador D Evers R Groshkova T Charles V Martin A Forzisi L: Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010; 375: 1885-1895
  196. Ross S Peselow E: Pharmacotherapy of addictive disorders. Clin Neuropharmacol 2009; 32: 277-289
  197. O’Brien CP: Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005; 162: 1423-1431
  198. Ray LA Chin PF Miotto K: Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets 2010; 9: 13-22
  199. Altshuler HL Phillips PA Feinhandler DA: Alteration of ethanol self-administration by naltrexone. Life Sci 1980; 26: 679-688
  200. Gonzales RA Weiss F: Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 1998; 18: 10663-10671
  201. Roberts AJ McDonald JS Heyser CJ Kieffer BL Matthes HWD Koob GF Gold LH: μ-Opioid receptor knockout mice do not self-administer alcohol. I Pharmacol Exp Ther 2000; 293: 1002-1008
  202. Gardner EL Paredes W Smith D Zukin RS: Facilitation of brain stimulation reward by ∆9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism. Adv Biosci 1989; 75: 671-674
  203. Chen J Paredes W Li J Smith D Lowinson J Gardner EL: ∆9-Tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 1990; 102: 156-162
  204. Tanda G Pontieri FE di Chiara G: Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 1997; 276: 2048-2050
  205. Mason BJ Heyser CJ: Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 2010; 9: 23-32
  206. Ameisen O: Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol 2005; 40: 147-150
  207. Ameisen O: The End of My Addiction. New York, Farrar, Straus and Giroux, 2008;
  208. Addolorato G Leggio L: Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010; 16: 2113-2117
  209. Mason BJ Heyser CJ: The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010; 9: 177-188
  210. Roberts DCS Andrews MM Vickers GJ: Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology 1996; 15: 417-423
  211. Roberts DCS Andrews MM: Baclofen suppression of cocaine self-administration: demonstration using a discrete trials procedure. Psychopharmacology 1997; 131: 271-277
  212. Brebner K Phelan R Roberts DCS: Intra-VTA baclofen attenuates cocaine self-administration on a progressive ratio schedule of reinforcement. Pharmacol Biochem Behav 2000; 66: 857-862
  213. Brebner K Phelan R Roberts DCS: Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology 2000; 148: 314-321
  214. Roberts DCS Brebner K: GABA modulation of cocaine self-administration. Ann NY Acad Sci 2000; 909: 145-158
  215. Cousins MS Roberts DCS de Wit H: GABAB receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend 2002; 65: 209-220
  216. Jorenby DE Hays JT Rigotti NA Azoulay S Watsky EJ Williams KE Billing CB Gong J Reeves KR: Efficacy of varenicline, an α4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63
  217. Garrison GD Dugan SE: Varenicline: a first-line treatment option for smoking cessation. Clin Ther 2009; 31: 463-491
  218. Spiller K Xi ZX Li X Ashby CR Jr Callahan PM Tehim A Gardner EL: Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of α4ß2 nicotinic receptors in rats. Neuropharmacology 2009; 57: 60-66
  219. Glynn DA Cryan JF Kent P Flynn RA Kennedy MP: Update on smoking cessation therapies. Adv Ther 2009; 26: 369-382
  220. Meyer JH Goulding VS Wilson AA Hussey D Christensen BK Houle S: Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 2002; 163: 102-105
  221. Semmer JE Martin BR Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000; 295: 321-327
  222. Froimowitz M Wu KM Moussa A Haidar RM Jurayj J George C Gardner EL: Slow-onset, long-duration 3-(3’,4’-dichlorophenyl)-1-indanamine monoamine reuptake blockers as potential medications to treat cocaine abuse. J Med Chem 2000; 43: 4981-4992
  223. Desai RI Kopajtic TA Koffarnus M Newman AH Katz JL: Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 2005; 25: 1889-1893
  224. Gardner EL Liu X Paredes W Giordano A Spector J Lepore M Wu KM Froimowitz M: A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction. Neuropharmacology 2006; 51: 993-1003
  225. Tanda G Newman AH Katz JL: Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 2009; 57: 253-289
  226. Peng X-Q Xi Z-X Li X Spiller K Li J Chun L Wu K-M Froimowitz M Gardner EL: Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications. Neuropsycho-pharmacology 2010; 35: 2564-2578
  227. Carlezon WA Jr Wise RA: Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 1996; 16: 3112-3122
  228. Kushner SA Dewey SL Kornetsky C: Gamma-vinyl GABA attenuates cocaine-induced lowering of brain stimulation reward thresholds. Psychopharmacology 1997; 133: 383-388
  229. Dewey SL Morgan AE Ashby CR Jr Horan B Kushner SA Logan J Volkow ND Fowler JS Gardner EL Brodie JD: A novel strategy for the treatment of cocaine addiction. Synapse 1998; 30: 119-129
  230. Dewey SL Brodie JD Gerasimov M Horan B Gardner EL Ashby CR Jr: A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999; 31: 76-86
  231. Kushner SA Dewey SL Kornetsky C: The irreversible γ-aminobutyric acid (GABA) transaminase inhibitor γ-vinyl-GABA blocks cocaine self-administration in rats. J Pharmacol Exp Ther 1999; 290: 797-802
  232. Gerasimov MR Ashby CR Jr Gardner EL Mills MJ Brodie JD Dewey SL: Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999; 34: 11-19
  233. Paul M Dewey SL Gardner EL Brodie JD Ashby CR Jr: Gamma-vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse 2001; 41: 219-220
  234. Gardner EL Schiffer WK Horan BA Highfield D Dewey SL Brodie JD Ashby CR Jr: Gamma-vinyl GABA, an irreversible inhibitor of GABA transaminase, alters the acquisition and expression of cocaine-induced sensitization in male rats. Synapse 2002; 46: 240-250
  235. Brodie JD Figueroa E Dewey SL: Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003; 50: 261-265
  236. Peng X-Q Li X Gilbert JG Pak AC Ashby CR Jr Brodie JD Dewey SL Gardner EL Xi Z-X: Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. Drug Alcohol Depend 2008; 97: 216-225
  237. DeMarco A Dalal RM Pai J Aquilina SD Mullapudi U Hammel C Kothari SK Kahanda M Liebling CN Patel V Schiffer WK Brodie JD Dewey SL: Racemic gamma vinyl-GABA (R,SGVG) blocks methamphetamine-triggered reinstatement of conditioned place preference. Synapse 2009; 63: 87-94
  238. Brodie JD Case BG Figueroa E Dewey SL Robinson JA Wanderling JA Laska EM: Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009; 166: 1269-1277
  239. Gardner EL Paredes W Smith D Donner A Milling C Cohen D Morrison D: Facilitation of brain stimulation reward by ∆9-tetrahydrocannabinol. Psychopharmacology 1988; 96: 142-144
  240. Gardner EL Lowinson JH: Marijuana’s interaction with brain reward systems: update 1991. Pharmacol Biochem Behav 1991; 40: 571-580
  241. Lepore M Vorel SR Lowinson J Gardner EL: Conditioned place preference induced by ∆9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci 1995; 56: 2073-2080
  242. de Vries TJ Homberg JR Binnekade R Raasø H Schoffelmeer ANM: Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psycho-pharmacology 2003; 168: 164-169
  243. Fattore L Spano MS Cossu G Deiana S Fratta W: Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 2003; 17: 1723-1726
  244. Anggadiredja K Nakamichi M Hiranita T Tanaka H Shoyama Y Watanabe S Yamamoto T: Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsycho-pharmacology 2004; 29: 1470-1478
  245. Spano MS Fattore L Cossu G Deiana S Fadda P Fratta W: CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 2004; 143: 343-350
  246. Yamamoto T Anggadiredja K Hiranita T: New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking. J Pharmacol Sci 2004; 96: 382-388
  247. Gardner EL: Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005; 81: 263-284
  248. Fattore L Spano S Cossu G Deiana S Fadda P Fratta W: Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 2005; 48: 1097-1104
  249. le Foll B Goldberg SR: Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005; 312: 875-883
  250. Economidou D Mattioli L Cifani C Perfumi M Massi M Cuomo V Trabace L Ciccocioppo R: Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 2006; 183: 394-403
  251. Fagerström K Balfour DJ: Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Exp Opin Investig Drugs 2006; 15: 107-116
  252. Li X Hoffman AF Peng X-Q Lupica CR Gardner EL Xi Z-X: Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice. Psychopharmacology 2009; 204: 1-11
  253. Uys JD LaLumiere RT: Glutamate: the new frontier in pharmacotherapy for cocaine addiction. CNS Neurol Disord Drug Targets 2008; 7: 482-491
  254. Kalivas PW: The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009; 10: 561-572
  255. Kalivas PW Lalumiere RT Knackstedt L Shen H: Glutamate transmission in addiction. Neuropharmacology 2009; 56: ((suppl 1)) 169-173
  256. Knackstedt LA Kalivas PW: Glutamate and reinstatement. Curr Opin Pharmacol 2009; 9: 59-64
  257. Olive MF: Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr Drug Abuse Rev 2009; 2: 83-98
  258. Moussawi K Kalivas PW: Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. Eur J Pharmacol 2010; 639: 115-122
  259. Schmidt HD Pierce RC: Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction. Ann NY Acad Sci 2010; 1187: 35-75
  260. Wise RA Morales M: A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Res 2010; 1314: 38-43
  261. Li X Gardner EL Xi Z-X: The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats. Neuro-pharmacology 2008; 54: 542-551
  262. Li X Li J Gardner EL Xi Z-X: Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats. J Neuro-chem 2010; 114: 1368-1380
  263. Peng X-Q Li J Gardner EL Ashby CR Jr Thomas A Wozniak K Slusher BS Xi Z-X: Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats. Eur J Pharmacol 2010; 627: 156-161
  264. Xi Z-X Kiyatkin M Li X Peng X-Q Wiggins A Spiller K Li J Gardner EL: N-acetyl-aspartatylglutamate (NAAG) attenuates cocaine-enhanced brain-stimulation reward and cocaine self-administration in rats. Neuropharmacology 2010; 58: 304-313
  265. Xi Z-X Li X Peng X-Q Li J Chun L Gardner EL Thomas AG Slusher BS Ashby CR Jr: Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism. J Neurochem 2010; 112: 564-576
  266. Valdez GR Koob GF: Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav 2004; 79: 671-689
  267. Funk CK O’Dell LE Crawford EF Koob GF: Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 2006; 26: 11324-11332
  268. Chu K Koob GF Cole M Zorrilla EP Roberts AJ: Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacol Biochem Behav 2007; 86: 813-821
  269. Funk CK Zorrilla EP Lee MJ Rice KC Koob GF: Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 2007; 61: 78-86
  270. George O Ghozland S Azar MR Cottone P Zorrilla EP Parsons LH O’Dell LE Richardson HN Koob GF: CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. Proc Natl Acad Sci USA 2007; 104: 17198-17203
  271. Gilpin NW Richardson HN Koob GF: Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. Alcohol Clin Exp Res 2008; 32: 1535-1542
  272. Ji D Gilpin NW Richardson HN Rivier CL Koob GF: Effects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats. Behav Pharmacol 2008; 19: 1-12
  273. Papaleo F Ghozland S Ingallinesi M Roberts AJ Koob GF Contarino A: Disruption of the CRF2 receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology 2008; 33: 2878-2887
  274. Specio SE Wee S O’Dell LE Boutrel B Zorrilla EP Koob GF: CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology 2008; 96: 473-482
  275. Greenwell TN Funk CK Cottone P Richardson HN Chen SA Rice KC Zorrilla EP Koob GF: Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol 2009; 14: 130-143
  276. Koob GF: Brain stress systems in the amygdala and addiction. Brain Res 2009; 1293: 61-75
  277. Koob GF: The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 2010; 1314: 3-14
  278. Zorrilla EP Koob GF: Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 2010; 5: 371-383


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50